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Background
Recent groups have shown that the immunological efficacy
of vaccines could be increased by encoding targeted muta-
tions that enhance the binding affinity between the
encoded epitopes and the MHC-TCR complex. In this
study, we sought to examine the anti-tumor efficacy of a
DNA vaccine targeting SSX-2, a cancer-testis antigen
(CTA) expressed by prostate tumors, containing muta-
tions designed to enhance the affinity of the reactive epi-
topes for the MHC.
Methods
A mouse sarcoma line engineered to express human HLA-
A2 and SSX-2 was subcutaneously implanted into the hind
flanks of C57BL/6 mice engineered to express HLA-A2
and not express mouse MHC types (HHDII-DRI mice).
Mice were then treated with either a control DNA vaccine,
a plasmid encoding the native SSX-2, or a plasmid encod-
ing SSX-2 with optimized HLA-A2-binding epitopes, and
tumor growth was followed.
Results
Immunization of mice with plasmid encoding native or
epitope-optimized SSX-2 elicited SSX-2 specific HLA-A2-
restricted CD8+ T cells as measured by IFNg ELISpot that
were able to lyse SSX-2-expressing target cells. Despite a
greater frequency of SSX-2-specific CD8+ T cells detect-
able following immunization with the optimized vector,
immunization with the optimized vector had an inferior
anti-tumor response in vivo compared with the native
SSX-2 vaccine. The SSX-2-specific CD8+ T cells elicited
from the optimized vaccine expressed higher levels of
programmed death-1 (PD-1) compared to those elicited
from the native SSX-2- vaccine, and its ligand PD-L1
was shown to be induced on the surface of tumors follow-
ing immunization and could be induced in vitro by co-
culturing with splenocytes from immunized animals.
Ongoing studies are evaluating the efficacy of immuniza-
tion with concurrent blockade of the PD-1 axis.
Conclusions
Although much work has been directed at developing
optimized cancer vaccines, our work suggests that the
PD-1/PD-L1 axis serves as a dominant compensatory
mechanism of resistance to this approach. Optimal next-
generation DNA vaccines will likely need to be designed
in such a way to either avoid or block the PD-1 regulatory
pathway in order to increase their anti-tumor efficacy.
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